Cibc World Markets Corp Boosts Holdings in DaVita Inc. (NYSE:DVA)

Cibc World Markets Corp boosted its stake in DaVita Inc. (NYSE:DVA) by 8.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,194 shares of the company’s stock after acquiring an additional 571 shares during the period. Cibc World Markets Corp’s holdings in DaVita were worth $1,076,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of DVA. Amundi boosted its position in shares of DaVita by 116.4% in the 4th quarter. Amundi now owns 446,386 shares of the company’s stock valued at $68,726,000 after purchasing an additional 240,126 shares during the period. FMR LLC boosted its holdings in shares of DaVita by 659.9% in the third quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after acquiring an additional 154,061 shares during the period. Skandinaviska Enskilda Banken AB publ grew its position in shares of DaVita by 256.8% during the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company’s stock worth $24,301,000 after acquiring an additional 116,758 shares during the last quarter. Glenmede Trust Co. NA increased its holdings in shares of DaVita by 731.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock valued at $20,207,000 after acquiring an additional 108,446 shares during the period. Finally, JPMorgan Chase & Co. raised its position in DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after purchasing an additional 92,014 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Price Performance

Shares of DVA opened at $148.25 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The stock’s 50 day moving average is $158.53 and its two-hundred day moving average is $157.48. DaVita Inc. has a twelve month low of $125.64 and a twelve month high of $179.60. The firm has a market capitalization of $11.86 billion, a PE ratio of 13.80, a P/E/G ratio of 1.07 and a beta of 0.99.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Research analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on DVA shares. Cowen reissued a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. Barclays raised their price target on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on DaVita in a research report on Friday, February 21st. Finally, StockNews.com lowered DaVita from a “buy” rating to a “hold” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, DaVita currently has an average rating of “Hold” and an average target price of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.